Sergey Voloshin

Statistics

Publications

Citations

1.2K

H-Index

Active since

2016

Affiliations

Russian Research Institute of Hematology and Transfusiology(Current)

Janssen (United States)

Copenhagen University Hospital

Janssen (Belgium)

City Clinical Hospital

Sergey Voloshin is an author at Russian Research Institute of Hematology and Transfusiology specializing in medicine, pharmacotherapy, and pharmacology.

ORCID

Publications per year

2016–2024

Publications

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Delphine Réa, Michael J. Mauro, Carla Boquimpani et al. · Blood · 2021 · 336 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

Arnon P. Kater, Carolyn Owen, Carol Moreno et al. · NEJM Evidence · 2022 · 226 citations

Medicine, Oncology, Pharmacotherapy +17

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial

Marek Trněný, Thierry Lamy, Jan Walewski et al. · The Lancet Oncology · 2016 · 156 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Carsten Utoft Niemann, Talha Munir, Carol Moreno et al. · The Lancet Oncology · 2023 · 139 citations · Full text

Life Sciences, Hematology, Immunology +7

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Andreas Hochhaus, Delphine Réa, Carla Boquimpani et al. · Leukemia · 2023 · 135 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

1–5 of 16